(Q33332394)
Statements
1 reference
Phase I study of AG2034, a targeted GARFT inhibitor, administered once every 3 weeks (English)
1 reference
Roberts JD
1 reference
Shibata S
1 reference
Spicer DV
1 reference
McLeod HL
1 reference
Tombes MB
1 reference
Kyle B
1 reference
Carroll M
1 reference
Sheedy B
1 reference
Collier MA
1 reference
Pithavala YK
1 reference
Paradiso LJ
1 reference
Clendeninn NJ
1 reference
1 January 2000
1 reference
1 reference
45
1 reference
423-427
1 reference
Identifiers
1 reference
1 reference